Doxazosin inhibits monocyte chemotactic protein 1-directed migration of human monocytes

Journal of Cardiovascular Pharmacology

Volumn 37, Issue 5, 2001, Pages 532-539

  Kintscher, Ulrich ^a,b   Kon, Dedrick ^a   Wakino, Shu ^a   Goetze, Stephan ^b   Graf, Kristof ^b   Fleck, Eckart ^b   Hsueh, Willa A ^a   Law, Ronald E ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Doxazosin; Matrix metalloproteinase; Migration; Monocyte; Tissue inhibitors of matrix metalloproteinase

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; GELATINASE B; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PHENOXYBENZAMINE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; ATHEROSCLEROSIS; CELL MIGRATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL;

ADRENERGIC ALPHA-ANTAGONISTS; CELL MOVEMENT; CHEMOKINE CCL2; DOXAZOSIN; HUMANS; MATRIX METALLOPROTEINASE 9; MONOCYTES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR CELLS, CULTURED;

EID: 0035028109     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200105000-00005     Document Type: Article

References (23)

1. Atherosclerosis: An inflammatory disease
2. Endothelial-leukocyte adhesion molecules in human disease
3. Leucocyte-endothelial interactions and regulation of leucocyte migration
4. Matrix metalloproteinase-9 (92 kDa gelatinase/type IV collagenase) from U937 monoblastoid cells: Correlation with cellular invasion
5. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
6. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions
7. Doxazosin inhibits proliferation and migration of human vascular smooth- Muscle cells independent of alpha-1 adrenergic receptor antagonism
8. Doxazosin inhibits retinoblastoma protein phosphorylation and G(1)→S transition in human coronary smooth muscle cells
9. Long-term reduction of intimal hyperplasia by the selective alpha-1 adrenergic antagonist doxazosin
10. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells
11. Modified proenzymes as artificial substrates for proteolytic enzymes: Colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase
12. Tissue inhibitor of matrix metalloproteinases-1 impairs arterial neointima formation after vascular injury in mice
13. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice
14. Effect of doxazosin on plasma lipids and atherogenesis: A preliminary report
15. Doxazosin and cholestyramine similarly decrease fatty streak formation in the aortic arch of hyperlipidemic hamsters
16. Dose-related effects of doxazosin on plasma lipids and aortic fatty streak formation in the hypercholesterolemic hamster model
17. Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodelihg in the injured rat carotid artery
18. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation
19. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention
20. A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension
21. Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension
22. Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. The Doxazosin-Captopril in Hypercholesterolemic Hypertensives Study
23. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive lipid-lowering treatment to prevent heart attack trial (ALLHAT)